Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
70 hedge funds and large institutions have $322M invested in Blueprint Medicines in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 9 closing their positions.
26,347% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $43K
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 73 → 70 (-3)
32% less capital invested
Capital invested by funds: $474M → $322M (-$152M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$7.15M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$6.79M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$6.28M |
| 5 |
VAM
Visium Asset Management
New York
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14.3M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$10.8M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$4.33M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.62M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.63M |
BPMC Hedge Fund Activity: Q1 2016 in Review
70 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2016, worth a combined $322M — down 32% from $474M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BPMC and 6 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 30 added.
The largest buyer was Fidelity Investments, adding an estimated $9.6M. The largest seller was RA Capital Management, cutting an estimated $14.3M.
- 70 institutional investors held Blueprint Medicines (BPMC) as of Q1 2016, down from 73 in Q4 2015.
- Funds reported $322M of Blueprint Medicines stock for Q1 2016, down 32% quarter-over-quarter.
- 6 funds opened new Blueprint Medicines positions in Q1 2016 and 9 closed out, a net change of -3 holders.
- The largest Blueprint Medicines buyer in Q1 2016 was Fidelity Investments, an estimated $9.6M added.
- The largest Blueprint Medicines seller in Q1 2016 was RA Capital Management, an estimated $14.3M sold.
Based on aggregated 13F filings for Q1 2016.